248 related articles for article (PubMed ID: 25209137)
21. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.
Hussain S; Siddiqui AN; Habib A; Hussain MS; Najmi AK
Rheumatol Int; 2018 Nov; 38(11):1999-2014. PubMed ID: 30159775
[TBL] [Abstract][Full Text] [Related]
22. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
[TBL] [Abstract][Full Text] [Related]
23. Effect of long-term proton pump inhibitors on bone mineral density.
Romdhane H; Ayadi S; Elleuch N; Abdelghani K
Tunis Med; 2018 Mar; 96(3):193-197. PubMed ID: 30325487
[TBL] [Abstract][Full Text] [Related]
24. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of vitamin D in relation to bone health.
Cranney A; Horsley T; O'Donnell S; Weiler H; Puil L; Ooi D; Atkinson S; Ward L; Moher D; Hanley D; Fang M; Yazdi F; Garritty C; Sampson M; Barrowman N; Tsertsvadze A; Mamaladze V
Evid Rep Technol Assess (Full Rep); 2007 Aug; (158):1-235. PubMed ID: 18088161
[TBL] [Abstract][Full Text] [Related]
26. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
McGowan B; Bennett K; Barry M
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
[TBL] [Abstract][Full Text] [Related]
27. Proton pump inhibitors use and change in bone mineral density.
Arj A; Razavi Zade M; Yavari M; Akbari H; Zamani B; Asemi Z
Int J Rheum Dis; 2016 Sep; 19(9):864-8. PubMed ID: 27242025
[TBL] [Abstract][Full Text] [Related]
28. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
29. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Lau YT; Ahmed NN
Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
[TBL] [Abstract][Full Text] [Related]
30. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
31. Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study.
Patel N; Fayed M; Faldu P; Maroun W; Chandarana J
Cureus; 2022 Aug; 14(8):e28429. PubMed ID: 36176864
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
[TBL] [Abstract][Full Text] [Related]
34. The relationship between proton pump inhibitor adherence and fracture risk in the elderly.
Ding J; Heller DA; Ahern FM; Brown TV
Calcif Tissue Int; 2014 Jun; 94(6):597-607. PubMed ID: 24706060
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure.
Targownik LE; Goertzen AL; Luo Y; Leslie WD
Am J Gastroenterol; 2017 Jan; 112(1):95-101. PubMed ID: 27845341
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitors and bone fractures?
Laine L
Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S21-6. PubMed ID: 19262543
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients.
Mello M; Weideman RA; Little BB; Weideman MW; Cryer B; Brown GR
Dig Dis Sci; 2012 Sep; 57(9):2416-22. PubMed ID: 22615013
[TBL] [Abstract][Full Text] [Related]
38. Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.
Awaisu A; Hamou F; Mekideche L; El Muabby N; Mahfouz A; Mohammed S; Saad A
Int J Clin Pharm; 2016 Apr; 38(2):353-61. PubMed ID: 26749343
[TBL] [Abstract][Full Text] [Related]
39. The relationship between long-term proton pump inhibitor therapy and skeletal frailty.
Lau AN; Tomizza M; Wong-Pack M; Papaioannou A; Adachi JD
Endocrine; 2015 Aug; 49(3):606-10. PubMed ID: 25948072
[TBL] [Abstract][Full Text] [Related]
40. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients.
Kirkpantur A; Altun B; Arici M; Turgan C
Int J Clin Pract; 2009 Feb; 63(2):261-8. PubMed ID: 19196364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
